MACK-3 (combination of hoMa, Ast and CK18): A promising novel biomarker for fibrotic non-alcoholic steatohepatitis.

Introduction: MACK-3 (combination of hoMa, Ast and CK18) was reported to be a good biomarker for the diagnosis of fibrotic non-alcoholic steatohepatitis (NASH). However, there is no external validation to date.

Aim: To evaluate the accuracy of MACK-3 for the diagnosis of fibrotic NASH.

Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.

Background And Aim: The recommendation in regard to screening for non-alcoholic fatty liver disease (NAFLD) among type 2 diabetes mellitus (T2DM) patients differs in major guidelines. The aim of this paper was to study the prevalence of NALFD and advanced fibrosis among T2DM patients.

Methods: This is a cross-sectional study of consecutive adult T2DM patients attending the Diabetes Clinic of a university hospital.